CA
NZ
UK
AU
IND
US
Motorola Solutions, Inc. filed a Form 8-K on August 17, 2026, disclosing the closing of an underwritten public offering of two tranches of senior notes totaling $950,000,000 in aggregate principal amount.
Repay Holdings Corporation filed a Form 8-K/A (Amendment No. 1) on August 17, 2026, amending its original June 1, 2026 Current Report to include required financial statements and unaudited pro forma financial information related to its completed acquisition of KUBRA Holdings, Inc. and KUBRA …
Fastly, Inc. filed a Form 8-K on August 17, 2026, disclosing that it entered into a Fourth Amendment to its Credit Agreement, increasing its senior secured revolving credit facility and extending its maturity date, among other changes.
IDEX Corporation filed a current report on August 17, 2026, disclosing that director L. Paris Watts-Stanfield resigned from its Board of Directors effective August 13, 2026, reducing the board from ten to nine members.
Horizon Bancorp, Inc. filed a Form 8-K on August 17, 2026, disclosing that its Board of Directors increased in size from 11 to 13 members and elected Nicholas J. Ritter and Charles W. Sulerzyski as independent directors to the Class of 2027.
Turn Therapeutics Inc. filed a Form 8-K on August 17, 2026, disclosing a private placement of common stock that closed under securities purchase agreements dated August 14, 2026.
Sonida Senior Living, Inc. filed a current report with the SEC on August 17, 2026, voluntarily providing updated unaudited pro forma condensed combined financial statements reflecting its March 11, 2026 acquisition of CNL Healthcare Properties, Inc.
Universal Health Services, Inc. filed a current report on August 17, 2026, disclosing the completed acquisition of Talkspace, Inc. and a $400 million borrowing under a delayed draw term loan facility to help finance the transaction.
Aon plc filed an 8-K with the U.S. Securities and Exchange Commission on August 17, 2026, disclosing that Chief Financial Officer Edmund Reese transitioned out of his role that same day and that Nadin Virani was appointed interim Chief Financial Officer effective immediately.
Maze Therapeutics, Inc. filed a current report on Form 8-K on August 17, 2026, disclosing the appointment of Paula A. Johnson, M.D., M.P.H. and Sophie Kornowski, Pharm.D. to its Board of Directors, effective August 13, 2026.
Please wait processing your request...